Cellectis Presents Preclinical Data for .HEAL-101 at ESGCT 2026
Cellectis announced positive preclinical data for its in vivo gene-editing candidate .HEAL-101, which targets APOC3 for the treatment of severe hypertriglyceridemia.
Stocks · News reference
Cellectis Reports Monthly Information on Share Capital and Voting Rights
Cellectis S.A. has released its mandatory monthly disclosure regarding the total number of shares and voting rights composing its share capital as of October 31, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Cellectis S.A. announced on September 14, 2026, that it would discontinue CAR-T cell therapy development (lasme-cel and eti-cel) to prioritize in vivo gene editing therapies, citing limited cash resources. The announcement triggered a 40.97% stock price decline, prompting a securities fraud investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders.
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is investigating Cellectis S.A. for potential securities law violations following the company's September 14, 2026 announcement to discontinue CAR-T cell therapies (lasme-cel and eti-cel) and prioritize in vivo gene editing therapies due to limited cash resources. The announcement triggered a 40.97% stock price decline, causing investor losses.
Cellectis shares are trading lower after Barclays downgraded the stock from Overweight to Underweight rating and lowered its price target from $9 to $1.3.
This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Analysts downgraded NU, BAK, CLLS and CBZ; price targets for NU, BAK and CLLS were cut sharply.
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.